Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
|
cisplatin • carboplatin • sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)